BidaskScore Reports Akari Therapeutics (AKTX) Upgrade; American Financial Group Cut Its Sinclair Broadcast Group (SBGI) Stake

Akari Therapeutics, Plc (NASDAQ:AKTX) Logo

New York-listed Akari Therapeutics (NASDAQ:AKTX), was increased by analysts at BidaskScore. BidaskScore increased its rating on the $39.92 million market cap company to a Buy.

American Financial Group Inc decreased Sinclair Broadcast Group Inc (SBGI) stake by 38.6% reported in 2019Q2 SEC filing. American Financial Group Inc sold 352,425 shares as Sinclair Broadcast Group Inc (SBGI)’s stock rose 10.71%. The American Financial Group Inc holds 560,624 shares with $30.07M value, down from 913,049 last quarter. Sinclair Broadcast Group Inc now has $3.09 billion valuation. The stock decreased 1.79% or $0.61 during the last trading session, reaching $33.5. About 825,804 shares traded or 0.08% up from the average. Sinclair Broadcast Group, Inc. (NASDAQ:SBGI) has risen 94.39% since December 4, 2018 and is uptrending. It has outperformed by 94.39% the S&P500. Some Historical SBGI News: 02/04/2018 – President Trump says Sinclair Broadcast Group is “far superior” to news outlets such as CNN and “Fake NBC, which is a total joke.”; 09/05/2018 – 21st Century Fox to Acquire Seven Stations from Sinclair Broadcast Group; 04/04/2018 – New York Post: Sinclair producer resigns as backlash mounts over `fake news’ script; 06/04/2018 – Register Guard: Don’t underestimate Fox, Sinclair; 24/04/2018 – Sinclair Agrees to Sell 23 TV Stations as Part of Tribune Deal; 23/04/2018 – DJ Sinclair Broadcast Group Inc Clas, Inst Holders, 1Q 2018 (SBGI); 09/05/2018 – Tribune/Sinclair divest package gets DoJ nod; 03/04/2018 – The real danger in Sinclair Broadcast’s ‘fake news’ scandal; 02/04/2018 – Sinclair Responds to Media Reports; 24/04/2018 – Sinclair to Sell TV Stations in Bid to Secure Tribune Deal Approval

Analysts await Sinclair Broadcast Group, Inc. (NASDAQ:SBGI) to report earnings on February, 26. They expect $1.22 earnings per share, down 41.90% or $0.88 from last year’s $2.1 per share. SBGI’s profit will be $112.39M for 6.86 P/E if the $1.22 EPS becomes a reality. After $1.15 actual earnings per share reported by Sinclair Broadcast Group, Inc. for the previous quarter, Wall Street now forecasts 6.09% EPS growth.

Investors sentiment decreased to 0.86 in 2019 Q2. Its down 0.15, from 1.01 in 2019Q1. It is negative, as 38 investors sold SBGI shares while 78 reduced holdings. 72 funds opened positions while 45 raised stakes. 54.67 million shares or 1.85% less from 55.70 million shares in 2019Q1 were reported. Whittier Trust invested 0% of its portfolio in Sinclair Broadcast Group, Inc. (NASDAQ:SBGI). Moreover, Pnc Financial Services Group Inc has 0% invested in Sinclair Broadcast Group, Inc. (NASDAQ:SBGI) for 7,306 shares. Citadel Advsr Lc accumulated 771,234 shares or 0.02% of the stock. Metropolitan Life Insur New York holds 0.02% of its portfolio in Sinclair Broadcast Group, Inc. (NASDAQ:SBGI) for 20,647 shares. Mackay Shields invested in 0.06% or 168,530 shares. Brookstone Capital Mngmt reported 0.13% stake. Delaware-based Dupont Cap Management Corporation has invested 0.01% in Sinclair Broadcast Group, Inc. (NASDAQ:SBGI). California Public Employees Retirement System invested in 0.01% or 127,390 shares. Cyrus Capital Partners Limited Partnership owns 25,000 shares for 0.16% of their portfolio. Moreover, Brandywine Inv Mngmt Ltd Llc has 0% invested in Sinclair Broadcast Group, Inc. (NASDAQ:SBGI) for 51 shares. Stonebridge Cap Advsrs Limited Company holds 0% of its portfolio in Sinclair Broadcast Group, Inc. (NASDAQ:SBGI) for 200 shares. State Bank Of Mellon Corporation invested 0.02% in Sinclair Broadcast Group, Inc. (NASDAQ:SBGI). Employees Retirement Association Of Colorado has invested 0% of its portfolio in Sinclair Broadcast Group, Inc. (NASDAQ:SBGI). Parametric Associate Lc has invested 0.01% in Sinclair Broadcast Group, Inc. (NASDAQ:SBGI). Sterling Cap Mgmt Ltd Liability Corporation holds 32,680 shares.

Since July 10, 2019, it had 1 insider purchase, and 0 insider sales for $21.76 million activity. Another trade for 395,000 shares valued at $21.76 million was bought by SMITH DAVID D.

More notable recent Sinclair Broadcast Group, Inc. (NASDAQ:SBGI) news were published by: which released: “Is Sinclair Broadcast Group, Inc. (SBGI) Going To Burn These Hedge Funds ? – Yahoo Finance” on December 04, 2019, also with their article: “Sinclair (SBGI) Beats Q3 Earnings and Revenue Estimates – Nasdaq” published on November 06, 2019, published: “How The Parts Add Up: PBS Targets $39 – Nasdaq” on December 02, 2019. More interesting news about Sinclair Broadcast Group, Inc. (NASDAQ:SBGI) were released by: and their article: “Consumer Sector Update for 11/20/2019: PDD,TGT,GHG,SBGI – Nasdaq” published on November 20, 2019 as well as‘s news article titled: “Noteworthy Wednesday Option Activity: JBL, SBGI, ROKU – Nasdaq” with publication date: November 06, 2019.

Among 2 analysts covering Sinclair Broadcast Group (NASDAQ:SBGI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Sinclair Broadcast Group has $6100 highest and $4800 lowest target. $54.50’s average target is 62.69% above currents $33.5 stock price. Sinclair Broadcast Group had 6 analyst reports since July 30, 2019 according to SRatingsIntel. B. Riley & Co maintained the shares of SBGI in report on Wednesday, August 14 with “Buy” rating.

The stock decreased 3.06% or $0.06 during the last trading session, reaching $1.9. About 264,127 shares traded. Akari Therapeutics, Plc (NASDAQ:AKTX) has declined 1.05% since December 4, 2018 and is downtrending. It has underperformed by 1.05% the S&P500. Some Historical AKTX News: 21/03/2018 – AKARI THERAPEUTICS PLC – QTRLY LOSS PER COMMON SHARE $0.01; 11/05/2018 – AKARI THERAPEUTICS SAYS ON MAY 8, DAVID HORN SOLOMON, RESIGNED AS CEO AND AS A MEMBER OF BOARD EFFECTIVE IMMEDIATELY – SEC FILING; 21/03/2018 – AKARI THERAPEUTICS PLC – AS OF DECEMBER 31, 2017, COMPANY HAD CASH AND CASH EQUIVALENTS OF $28.1 MLN; 11/05/2018 – AKTX: PROBE FOUND PERSONAL CHARGES ON CORPORATE CREDIT CARDS; 21/05/2018 – Akari Therapeutics: Investigation Revealed Former CEO Incurred Personal Charges on Corporate Credit Cards in Violation of Co Policy; 21/05/2018 – AKARI THERAPEUTICS GETS NOTICE RELATED TO DELAY IN 20-F FILING; 11/05/2018 – AKARI THERAPEUTICS CEO DAVID HORN SOLOMON RESIGNED; 11/05/2018 – AKARI THERAPEUTICS CEO RESIGNS FOR VIOLATION OF CO. POLICY; 21/03/2018 – Akari Therapeutics 4Q Loss/Shr 1c; 21/05/2018 – Akari Therapeutics Receives Notice Related to Delay in 20-F Filing

More notable recent Akari Therapeutics, Plc (NASDAQ:AKTX) news were published by: which released: “What Kind Of Shareholder Owns Most Akari Therapeutics, Plc (NASDAQ:AKTX) Stock? – Yahoo Finance” on November 18, 2019, also with their article: “Akari up 28% premarket on advancement of nomacopan – Seeking Alpha” published on December 02, 2019, published: “SKT, CLVS among premarket gainers – Seeking Alpha” on December 02, 2019. More interesting news about Akari Therapeutics, Plc (NASDAQ:AKTX) were released by: and their article: “63 Biggest Movers From Yesterday – Benzinga” published on December 04, 2019 as well as‘s news article titled: “44 Stocks Moving In Monday’s Mid-Day Session – Benzinga” with publication date: December 02, 2019.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company has market cap of $39.92 million. The Company’s lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. It currently has negative earnings. The firm is based in New York, New York.

Sinclair Broadcast Group, Inc. (NASDAQ:SBGI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.